Expression of pentose phosphate pathway-related proteins in breast cancer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose. The purpose of this study was to assess the expression of pentose phosphate pathway- (PPP-) related proteins and their significance in clinicopathologic factors of breast cancer. Methods. Immunohistochemical staining for PPP-related proteins (glucose-6-phosphate dehydrogenase [G6PDH], 6-phosphogluconolactonase [6PGL], 6-phosphogluconate dehydrogenase [6PGDH], and nuclear factor-erythroid 2-related factor 2 [NRF2]) was performed using tissue microarray (TMA) of 348 breast cancers. mRNA levels of these markers in publicly available data from the Cancer Genome Atlas project and Kaplan-Meier plotters were analyzed. Results. Expression of G6PDH and 6PGL was higher in HER-2 type (p < 0 001 and p = 0 009, resp.) and lower in luminal A type. 6PGDH expression was detected only in TNBC subtype (p < 0 001). G6PDH positivity was associated with ER negativity (p = 0 001), PR negativity (p = 0 001), and HER-2 positivity (p < 0 001), whereas 6PGL positivity was associated with higher T stage (p = 0 004). The 562 expression profile from the TCGA database revealed increased expression of G6PDH and 6PG in the tumor compared with normal adjacent breast tissue. The expression of G6PDH was highest in HER-2 type. HER-2 and basal-like subtypes showed higher expression of 6PGDH than luminal types. Conclusion. PPP-related proteins are differentially expressed in breast cancer according to molecular subtype, and higher expression of G6PDH and 6PGL was noted in HER-2 subtype.

Original languageEnglish
Article number9369358
JournalDisease markers
Volume2018
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

6-phosphogluconolactonase
Pentoses
Pentose Phosphate Pathway
Glucosephosphate Dehydrogenase
Phosphates
Phosphogluconate Dehydrogenase
Breast Neoplasms
Proteins
Tissue
Atlases
Microarrays
Tumors
Neoplasms
Breast
Genes
Genome
Databases
Staining and Labeling
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

@article{825cfadc6a67449cb2c215695a9388aa,
title = "Expression of pentose phosphate pathway-related proteins in breast cancer",
abstract = "Purpose. The purpose of this study was to assess the expression of pentose phosphate pathway- (PPP-) related proteins and their significance in clinicopathologic factors of breast cancer. Methods. Immunohistochemical staining for PPP-related proteins (glucose-6-phosphate dehydrogenase [G6PDH], 6-phosphogluconolactonase [6PGL], 6-phosphogluconate dehydrogenase [6PGDH], and nuclear factor-erythroid 2-related factor 2 [NRF2]) was performed using tissue microarray (TMA) of 348 breast cancers. mRNA levels of these markers in publicly available data from the Cancer Genome Atlas project and Kaplan-Meier plotters were analyzed. Results. Expression of G6PDH and 6PGL was higher in HER-2 type (p < 0 001 and p = 0 009, resp.) and lower in luminal A type. 6PGDH expression was detected only in TNBC subtype (p < 0 001). G6PDH positivity was associated with ER negativity (p = 0 001), PR negativity (p = 0 001), and HER-2 positivity (p < 0 001), whereas 6PGL positivity was associated with higher T stage (p = 0 004). The 562 expression profile from the TCGA database revealed increased expression of G6PDH and 6PG in the tumor compared with normal adjacent breast tissue. The expression of G6PDH was highest in HER-2 type. HER-2 and basal-like subtypes showed higher expression of 6PGDH than luminal types. Conclusion. PPP-related proteins are differentially expressed in breast cancer according to molecular subtype, and higher expression of G6PDH and 6PGL was noted in HER-2 subtype.",
author = "Junjeong Choi and Kim, {Eun Sol} and Koo, {Ja Seung}",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/9369358",
language = "English",
volume = "2018",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

Expression of pentose phosphate pathway-related proteins in breast cancer. / Choi, Junjeong; Kim, Eun Sol; Koo, Ja Seung.

In: Disease markers, Vol. 2018, 9369358, 01.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of pentose phosphate pathway-related proteins in breast cancer

AU - Choi, Junjeong

AU - Kim, Eun Sol

AU - Koo, Ja Seung

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose. The purpose of this study was to assess the expression of pentose phosphate pathway- (PPP-) related proteins and their significance in clinicopathologic factors of breast cancer. Methods. Immunohistochemical staining for PPP-related proteins (glucose-6-phosphate dehydrogenase [G6PDH], 6-phosphogluconolactonase [6PGL], 6-phosphogluconate dehydrogenase [6PGDH], and nuclear factor-erythroid 2-related factor 2 [NRF2]) was performed using tissue microarray (TMA) of 348 breast cancers. mRNA levels of these markers in publicly available data from the Cancer Genome Atlas project and Kaplan-Meier plotters were analyzed. Results. Expression of G6PDH and 6PGL was higher in HER-2 type (p < 0 001 and p = 0 009, resp.) and lower in luminal A type. 6PGDH expression was detected only in TNBC subtype (p < 0 001). G6PDH positivity was associated with ER negativity (p = 0 001), PR negativity (p = 0 001), and HER-2 positivity (p < 0 001), whereas 6PGL positivity was associated with higher T stage (p = 0 004). The 562 expression profile from the TCGA database revealed increased expression of G6PDH and 6PG in the tumor compared with normal adjacent breast tissue. The expression of G6PDH was highest in HER-2 type. HER-2 and basal-like subtypes showed higher expression of 6PGDH than luminal types. Conclusion. PPP-related proteins are differentially expressed in breast cancer according to molecular subtype, and higher expression of G6PDH and 6PGL was noted in HER-2 subtype.

AB - Purpose. The purpose of this study was to assess the expression of pentose phosphate pathway- (PPP-) related proteins and their significance in clinicopathologic factors of breast cancer. Methods. Immunohistochemical staining for PPP-related proteins (glucose-6-phosphate dehydrogenase [G6PDH], 6-phosphogluconolactonase [6PGL], 6-phosphogluconate dehydrogenase [6PGDH], and nuclear factor-erythroid 2-related factor 2 [NRF2]) was performed using tissue microarray (TMA) of 348 breast cancers. mRNA levels of these markers in publicly available data from the Cancer Genome Atlas project and Kaplan-Meier plotters were analyzed. Results. Expression of G6PDH and 6PGL was higher in HER-2 type (p < 0 001 and p = 0 009, resp.) and lower in luminal A type. 6PGDH expression was detected only in TNBC subtype (p < 0 001). G6PDH positivity was associated with ER negativity (p = 0 001), PR negativity (p = 0 001), and HER-2 positivity (p < 0 001), whereas 6PGL positivity was associated with higher T stage (p = 0 004). The 562 expression profile from the TCGA database revealed increased expression of G6PDH and 6PG in the tumor compared with normal adjacent breast tissue. The expression of G6PDH was highest in HER-2 type. HER-2 and basal-like subtypes showed higher expression of 6PGDH than luminal types. Conclusion. PPP-related proteins are differentially expressed in breast cancer according to molecular subtype, and higher expression of G6PDH and 6PGL was noted in HER-2 subtype.

UR - http://www.scopus.com/inward/record.url?scp=85048606484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048606484&partnerID=8YFLogxK

U2 - 10.1155/2018/9369358

DO - 10.1155/2018/9369358

M3 - Article

C2 - 29682102

AN - SCOPUS:85048606484

VL - 2018

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

M1 - 9369358

ER -